A monoclonal antibody directed against CD22, a molecule present on the surface of B-cells, which are a type of White Blood Cell (WBC) responsible for protecting the body against infections. This drug may be effective against a variety of diseases that involve abnormal B-cells, including cancers such as lymphoma. It binds to cells that express the CD22 molecule on their surface and results in cell death. It is now being tested in a number of worldwide trials in the treatment of lymphomas, leukemias and some immune diseases, such as lupus.
LymphoCide is a humanized monoclonal antibody and is less likely to cause allergic reactions when compared with other monoclonal antibodies, including Rituximab that contains very small amounts of protein sequences from mice. The exact role of Epratuzumab in lymphomas is being investigated, both after standard treatments as well as in the first management of non-Hodgkin’s lymphomas along with chemotherapy regimens, such as R-CHOP.